Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.50 |
| ▸ | FDPS | P14324 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829773 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL8885362 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL276738 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL277985 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL8885541 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL7866214 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL277395 | 0.98 | CA1 (0.64) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL276554 | 0.90 | — | — | |
| SCHEMBL3231557 | 0.83 | CA1 (0.71) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL1321582 | 0.83 | CA1 (0.71) | CA1ACE2GPR84FDPSFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779138-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2014-07-15 | — | — | US | disclosed |
| US-8563537-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1951231-B1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MED CENTER (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012134446-A1 | EPIANDROSTERONE AND/OR ANDROSTERONE DERIVATIVES AND METHOD OF USE THEREOF | SUTTER WEST BAY HOSPITALS doing business as CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2011-07-28 | — | — | US | disclosed |
| US-7875602-B2 | Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in cancer treatment in combination with radiotherapy; less toxic | SUTTER WEST BAY HOSPITALS (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | disclosed |
| US-7605262-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090105202-A1 | Androsterone Derivatives and Method of Use thereof | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1353673-A1 | CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
| EP-1137737-A1 | LIQUID CRYSTAL COMPOUND | Rolic AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000031211-A1 | LIQUID CRYSTAL COMPOUND | ROLIC AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105202-A1 | Androsterone Derivatives and Method of Use thereof | HSD17B11, CYP19A1, SHBG | CA1 3576/4885ACE2 3753/4885GPR84 1314/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | CA1 1273/4885ACE2 4763/4885GPR84 1490/4885 |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | ERCC2, CHEK1, ERCC4 | CA1 2738/4885ACE2 4594/4885GPR84 1950/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | CA1 3941/4885ACE2 4602/4885GPR84 1999/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | CA1 1273/4885ACE2 4763/4885GPR84 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.